BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:10 PM
 | 
Oct 29, 2009
 |  BC Extra  |  Clinical News

Genasense misses PFS endpoint

Genasense oblimersen from Genta Inc. (OTCBB:GETA) plus dacarbazine (DTIC) missed the co-primary endpoint of a significant improvement in progression-free survival (PFS) vs. DTIC and...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >